Oral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer
Authors
Ci, X. P.Chen, S. J.
Zhu, R.
Zarif, M.
Jain, R.
Guo, W. Y.
Ramotar, M.
Gong, L. S.
Xu, W. J.
Singh, O.
Mansouri, S.
Zadeh, G.
Wei, G. H.
Xu, W.
Bristow, Robert
Berlin, A.
Koritzinsky, M.
van der Kwast, T.
He, H. H.
Affiliation
Division of Cancer Sciences, University of Manchester, Manchester, UK. Christie NHS Trust and CRUK Manchester Institute and Cancer Centre, Manchester, UKIssue Date
2024
Metadata
Show full item recordAbstract
Background Tumor hypoxia is associated with prostate cancer (PCa) treatment resistance and poor prognosis. Pimonidazole (PIMO) is an investigational hypoxia probe used in clinical trials. A better understanding of the clinical significance and molecular alterations underpinning PIMO-labeled tumor hypoxia is needed for future clinical application. Here, we investigated the clinical significance and molecular alterations underpinning PIMO-labeled tumor hypoxia in patients with localized PCa, in order to apply PIMO as a prognostic tool and to identify potential biomarkers for future clinical translation.Methods A total of 39 patients with localized PCa were recruited and administered oral PIMO before undergoing radical prostatectomy (RadP). Immunohistochemical staining for PIMO was performed on 37 prostatectomy specimens with staining patterns evaluated and clinical association analyzed. Whole genome bisulfite sequencing was performed using laser-capture of microdissected specimen sections comparing PIMO positive and negative tumor areas. A hypoxia related methylation molecular signature was generated by integrating the differentially methylated regions with previously established RNA-seq datasets.Results Three PIMO staining patterns were distinguished: diffuse, focal, and comedo-like. The comedo-like staining pattern was more commonly associated with adverse pathology. PIMO-defined hypoxia intensity was positively correlated with advanced pathologic stage, tumor invasion, and cribriform and intraductal carcinoma morphology. The generated DNA methylation signature was found to be a robust hypoxia biomarker, which could risk-stratify PCa patients across multiple clinical datasets, as well as be applicable in other cancer types.Conclusions Oral PIMO unveiled clinicopathologic features of disease aggressiveness in localized PCa. The generated DNA methylation signature is a novel and robust hypoxia biomarker that has the potential for future clinical translation.Citation
Ci XP, Chen SJ, Zhu R, Zarif M, Jain R, Guo WY, et al. Oral pimonidazole unveils clinicopathologic and epigenetic features of hypoxic tumour aggressiveness in localized prostate cancer. BMC cancer. 2024 JUN 18;24(1).Journal
BMC CancerDOI
10.1186/s12885-024-12505-1PubMed ID
38890593Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1186/s12885-024-12505-1
Scopus Count
Collections
Related articles
- GBX2 Methylation Is a Novel Prognostic Biomarker and Improves Prediction of Biochemical Recurrence Among Patients with Prostate Cancer Negative for Intraductal Carcinoma and Cribriform Architecture.
- Authors: Jeyapala R, Savio AJ, Olkhov-Mitsel E, Kamdar S, Zhao F, Cuizon C, Liu RSC, Zlotta A, Fleshner N, van der Kwast T, Bapat B
- Issue date: 2019 May
- Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy.
- Authors: Geybels MS, Wright JL, Bibikova M, Klotzle B, Fan JB, Zhao S, Feng Z, Ostrander EA, Lin DW, Nelson PS, Stanford JL
- Issue date: 2016
- Correlation and colocalization of HIF-1α and pimonidazole staining for hypoxia in laryngeal squamous cell carcinomas: A digital, single-cell-based analysis.
- Authors: Swartz JE, Smits HJG, Philippens MEP, de Bree R, H A M Kaanders J, Willems SM
- Issue date: 2022 May
- Spatial analysis of microRNA regulation at defined tumor hypoxia levels reveals biological traits of aggressive prostate cancer.
- Authors: Skingen VE, Salberg UB, Hompland T, Fjeldbo CS, Helgeland H, Frikstad KM, Ragnum HB, Vlatkovic L, Hole KH, Seierstad T, Lyng H
- Issue date: 2024 Nov
- A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients.
- Authors: Salberg UB, Skingen VE, Fjeldbo CS, Hompland T, Ragnum HB, Vlatkovic L, Hole KH, Seierstad T, Lyng H
- Issue date: 2022 Jul